Compare Amgen, Inc. (AMGN) vs Remitly Global Inc (RELY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Remitly Global Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Remitly Global Inc trades at $23.62 (market cap $5.01B). The key difference: Amgen, Inc. is far larger — about 39.1× Remitly Global Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| AMGN | RELY | |
|---|---|---|
Market Cap | $196.12B | $5.01B |
Sector | Health | Technology |
52-Week High | $388.16 | $24.28 |
52-Week Low | $271.18 | $12.20 |
Enterprise Value | $241.41B | $4.40B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
RELY trades at $23.77, up 0.89% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q1 2026 EPS of $0.23, beating expectations, and raised full-year guidance to $1.96–$1.975 billion revenue. Recent news highlights a UAE license and market share gains.
Outlook is positive with 92% analyst buy ratings and a $26.75 consensus target, but high P/E of 49.52 and competitive pressures in remittance pose risks. Profitability has turned positive, with net income reaching $67.93M in 2025 after prior losses, signaling a sustainable growth trajectory if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
